- Motley Fool•5 hours ago
The FDA has approved Dupixent for moderate to severe eczema, making it the first non-topical drug to win regulatory support in the indication.
- American City Business Journals•yesterday
Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (AMGN).
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
SAN.PA: Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's range||83.48 - 84.67|
|52-week range||62.50 - 84.93|
|PE ratio (TTM)||23.19|
|Dividend & yield||3.35 (3.69%)|
|1y target est||N/A|